Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Nephroplus Health Services Kazakhstan LLP is a overseas step-down subsidiary of Nephrocare Health Services.
Dialysis Center Almaty LLP is a limited liability partnership incorporated under the laws of the Republic of Kazakhstan. The company is engaged in the business of providing dialysis services through its dialysis centres in Kazakhstan. The company had recorded turnover of KZT 527.44 million (approx. Rs 10.93 crore) for the calendar year 2025.
Nephrocare Health Services stated that this acquisition is in line with the company’s existing business and its strategy of expanding its dialysis services network in international markets. The acquisition is expected to strengthen the company’s presence and operating platform in Kazakhstan and support the further expansion of its dialysis services business in the region.
Nephrocare Health would acquire the said stake for a cash consideration of KZT 561.66 million (approx. Rs 11.63 crore), subject to downward adjustments, if any, in accordance with the terms of the SPA.
'The acquisition will be completed upon satisfaction or waiver, as applicable, of the conditions precedent and completion of the closing actions contemplated under the SPA,' Nephrocare Health Services said in a statement.
Nephrocare Health Services provides end-to-end dialysis care through a wide network of clinics across India and select international markets.
The company had reported 34.89% rise in consolidated net profit to Rs 31.97 crore on a 23.69% increase in revenue to Rs 281.75 crore in Q1 FY27 as compared with Q1 FY26.
The scrip rose 0.27% to currently trade at Rs 691.25 on the BSE.
The agreement is to acquire identified assets related to a dialysis centre in Quezon City, Philippines.
The acquisition pertains to a dialysis facility located at Duyan-Duyan, Project 3, Quezon City, and is being undertaken for a total consideration of PHP 30 million.
The company said the transaction is aimed at expanding its dialysis care footprint in the Philippines and will be executed in accordance with the terms and conditions of the agreement.
Nephrocare clarified that the seller is not related to the company, its promoters, or promoter group entities. The transaction does not qualify as a related-party transaction and does not involve any special rights or share issuance arrangements.
The compnay’s consolidated net profit rose 22.1% to Rs 30.37 crore on 21.2% increase in revenue from operations to Rs 265.62 crore in Q4 FY26 over Q4 FY25.
For the full year,net profit rose 14.52% to Rs 76.84 crore in the year ended March 2026 as against Rs 67.10 crore during the previous year ended March 2025. Sales rose 32.16% to Rs 998.85 crore in the year ended March 2026 as against Rs 755.81 crore during the previous year ended March 2025.